Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen (Nasdaq: CGEN) reported Q4 and full‑year 2025 results and a corporate update on March 2, 2026. Key items: $145.6M cash at year‑end, $65M upfront from AstraZeneca royalty monetization, expected cash runway into 2029, and CEO transition to Eran Ophir.
2025 revenue totaled $72.8M (Q4 $67.3M); net income was $35.3M for the year and Q4 net profit was $56.8M. Clinical progress includes COM701 MAIA‑ovarian and Gilead‑partnered GS‑0321 trials with MAIA interim analysis expected Q1 2027.
Compugen (NASDAQ: CGEN) said management will participate in two investor conferences in late Feb–early Mar 2026: Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) on Feb 26, 2026 and Leerink Partners 2026 Global Healthcare Conference (Miami) on Mar 9, 2026.
Both events include fireside chats and 1x1 meetings; live webcasts and replays will be available on the company's investor relations events page at www.cgen.com.
Compugen (NASDAQ: CGEN) will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.
Telephone access is available in the U.S. and internationally, and a replay will be posted on the company website after the live webcast.
Compugen (Nasdaq: CGEN) announced the appointment of Dr. Michele Holcomb as an independent director, effective February 11, 2026. Dr. Holcomb brings 30+ years in biotech, pharmaceuticals and healthcare services, including senior roles at Cardinal Health and Teva and a long tenure at McKinsey.
The company highlighted her experience in strategy, business development, partnerships and portfolio management as strengthening the board while Compugen advances multiple clinical programs, pharma partnerships and its AI/ML discovery platform.
Compugen (NASDAQ: CGEN) announced that it will monetize a portion of its rilvegostomig future royalties to AstraZeneca in a non-dilutive transaction dated Dec 17, 2025.
Key terms include an $65 million upfront payment and a potential $25 million milestone payment tied to the next BLA acceptance milestone, while Compugen retains the majority of future royalties and remains eligible for tiered royalties up to mid-single digits plus up to $195 million of potential regulatory and commercial milestones (including the $25 million).
Management says proceeds are expected to extend cash runway into 2029 to advance Compugen's clinical-stage immuno-oncology pipeline and partnered programs.
Compugen (NASDAQ: CGEN)/b) reported third-quarter 2025 results and a corporate update on Nov 10, 2025.Key items: $86.1M cash with runway into Q3 2027; Q3 revenue $1.9M versus $17.1M year-ago; net loss $6.98M ($0.07/share) vs prior quarter profit $1.28M. Clinical: pooled Phase 1 COM701 showed durable responses with median PFS 10.5 months in patients deriving benefit; MAIA-ovarian blinded randomized maintenance trial is enrolling in the U.S., Israel and France with interim analysis now estimated in Q1 2027. Corporate: GS-0321 (COM503) licensed to Gilead; partnership with AstraZeneca and Gilead carries >$1B potential milestones and royalties.
Compugen (Nasdaq: CGEN) announced management will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York City on Tuesday, November 11, 2025 from 3:20–3:50 PM ET.
A live webcast will be available on the company's Investor Relations website at www.cgen.com, with a replay posted after the event.
Compugen (Nasdaq: CGEN) announced it will release third quarter 2025 financial results on Monday, November 10, 2025 before U.S. markets open. Management will host a conference call and webcast to review results and provide a corporate update on November 10, 2025 at 8:30 AM ET. U.S. dial-in is 1-866-744-5399; international dial-in is +972-3-918-0644. The call will be available via live webcast on Compugen's website, with a replay posted after the live event.
AstraZeneca (AZN) and Daiichi Sankyo reported initial results from a TROPION-PanTumor03 sub-study showing DATROWAY (datopotamab deruxtecan) plus rilvegostomig produced a confirmed objective response rate (ORR) of 68.2% (95% CI: 45.1–86.1) and disease control rate (DCR) of 95.5% (80% CI: 83.4–99.5) in cisplatin-ineligible first-line metastatic urothelial cancer (n=22).
In the second-line, previously platinum-treated/immunotherapy-naïve cohort (n=18), ORR was 38.9% (95% CI: 17.3–64.3) and median progression-free survival (PFS) was 12.5 months (95% CI: 4.2–NR). Median duration of response was not reached in either cohort. Safety was consistent with known profiles: grade ≥3 treatment-related adverse events occurred in 18.2% (first-line) and 38.9% (second-line); adjudicated ILD events were 1 (4.5%) and 2 (11.1%), respectively.
Compugen (NASDAQ: CGEN) announced a pooled analysis of 60 evaluable patients with platinum resistant ovarian cancer showing COM701 was well tolerated with consistent, durable responses; the abstract was released by ESMO and a poster will be presented on October 18, 2025 in Berlin.
The analysis highlights stronger outcomes particularly in patients without liver metastases and supports testing COM701 as maintenance therapy in earlier, platinum sensitive disease in the ongoing MAIA-ovarian trial. An interim MAIA-ovarian analysis is planned once ~60 participants are evaluable, currently estimated by year-end 2026. Sites are active in the U.S. and Israel, with site activation initiated in France; the company expects cash to fund operations into 2027.